Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 2, 2010
[Fragment screening using surface plasmon resonance optical biosensor technology]Takaaki Miura
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|July 5, 2003
Establishment of standard values for the latency, interval and amplitude parameters of tibial nerve somatosensory evoked potentials (SEPs)Takaaki Miura, Masahiro Sonoo, Teruo Shimizu
Rinsho Shinkeigaku = Clinical Neurology|October 3, 2002
[An adult case of Moyamoya disease presenting with transient hemichorea]Takaaki Miura, Michiko Kobayashi, Masahiro Sonoo, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|December 25, 2009
Autonomous motion of vesicle via ion exchangeTakaaki Miura, Hideaki Oosawa, Makoto Sakai, et al.
Chemical & Pharmaceutical Bulletin|November 3, 2016
Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD)Terushige Muraoka, Mitsuaki Ide, Machiko Irie, et al.
Bioorganic & Medicinal Chemistry Letters|January 23, 2017
Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based screening of focused librariesTakaaki Miura, Atsushi Matsuo, Terushige Muraoka, et al.
Bioorganic & Medicinal Chemistry|July 25, 2016
Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD)Terushige Muraoka, Mitsuaki Ide, Kenji Morikami, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2012
Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitorsTakashi Chiba, Jun Ohwada, Hiroshi Sakamoto, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2011
Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug designTakaaki Miura, Takaaki A Fukami, Kiyoshi Hasegawa, et al.
Cancer Cell|April 22, 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsPiro Lito, Anna Saborowski, Jingyin Yue, et al.
Pageof 2